CAMBRIDGE, Mass., March 1 /PRNewswire/ -- Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, today announced that it will be presenting at the SG Cowen 26th Annual Health Care Conference in Boston. Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris, will provide an overview of the Company and discuss the Company’s strategy for discovering and developing first-in-class therapeutics that modulate sirtuins, the body’s own health-promoting proteins. His presentation will be delivered at 2:30pm EST on Monday, March 6th, 2006.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins, a recently discovered family of enzymes that promotes the body’s natural defense against disease. Also known as class III histone deacetylases (HDACs), sirtuins are attractive drug targets for diseases of aging, including metabolic and neurological diseases. Sirtris has built the dominant sirtuin intellectual property estate and know-how, with a comprehensive suite of reagents, proprietary assays, transgenic animal models, and biomarkers.
Sirtris Pharmaceuticals was founded by Rich Aldrich, Richard Pops, Paul Schimmel, David Sinclair and Christoph Westphal, and has raised $45 million in private equity from leading venture capital firms including Polaris Venture Partners, Techno Venture Management, Cardinal Partners, Skyline Ventures, Three Arch Partners, The Wellcome Trust, Novartis Bioventures Fund, Cargill Ventures, Hunt Ventures, and Red Abbey. The company’s headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.sirtrispharma.com.
Media Contact:
Kathryn Morris
845-635-9828
Sirtris Pharmaceuticals
CONTACT: Kathryn Morris of Sirtris Pharmaceuticals, +1-845-635-9828
Web site: http://www.sirtrispharma.com//
